CRSP vs. MSFT

Last updated Jun 13, 2026

CRSP (CRISPR Therapeutics AG) and MSFT (Microsoft Corporation) are both stocks. CRSP operates in Biotechnology (Healthcare), while MSFT operates in Software - Infrastructure (Technology). Over the past 5 years, CRSP returned -17.08%/yr vs 9.56%/yr for MSFT. At a 0.31 correlation, their price movements are largely independent.

Performance

CRSP vs. MSFT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CRISPR Therapeutics AG (CRSP) and Microsoft Corporation (MSFT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CRSP achieves a -5.03% return, which is significantly higher than MSFT's -18.85% return.

CRSP

• 1D: -0.86%
• 1M: 2.87%
• YTD: -5.03%
• 6M: -12.14%
• 1Y: 20.41%
• 3Y*: -6.43%
• 5Y*: -17.08%
• 10Y*: —

MSFT

• 1D: 0.10%
• 1M: -7.19%
• YTD: -18.85%
• 6M: -17.98%
• 1Y: -17.07%
• 3Y*: 6.16%
• 5Y*: 9.56%
• 10Y*: 24.39%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CRSP vs. MSFT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CRSP CRISPR Therapeutics AG	-5.03%	33.23%	-37.12%	54.00%	-46.36%	-50.51%	151.39%	113.18%	21.68%	15.89%
MSFT Microsoft Corporation	-18.85%	15.58%	12.93%	58.19%	-28.02%	52.48%	42.53%	57.56%	20.80%	40.73%

Correlation

The correlation between CRSP and MSFT is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.11
Correlation (3Y) Calculated over the trailing 3-year period	0.20
Correlation (5Y) Calculated over the trailing 5-year period	0.28
Correlation (All Time) Calculated using the full available price history since Oct 19, 2016	0.31

Over the past year, the correlation between CRSP and MSFT has dropped to 0.11 - well below their long-term average of 0.31, suggesting their price drivers have been diverging.

Fundamentals

Market Cap CRSP : $4.78B MSFT : $2.91T
EPS CRSP : -$6.24 MSFT : $16.79
PS Ratio CRSP : 1.11K MSFT : 9.16
PB Ratio CRSP : 2.64 MSFT : 7.02
Total Revenue (TTM) CRSP : $4.10M MSFT : $318.27B
Gross Profit (TTM) CRSP : -$171.17M MSFT : $217.41B
EBITDA (TTM) CRSP : -$509.21M MSFT : $200.96B

Return for Risk

CRSP vs. MSFT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRSP

CRSP Risk / Return Rank: 54
CRSP Sharpe Ratio Rank: 55
CRSP Sortino Ratio Rank: 55
CRSP Omega Ratio Rank: 52
CRSP Calmar Ratio Rank: 54
CRSP Martin Ratio Rank: 53

MSFT

MSFT Risk / Return Rank: 17
MSFT Sharpe Ratio Rank: 13
MSFT Sortino Ratio Rank: 15
MSFT Omega Ratio Rank: 14
MSFT Calmar Ratio Rank: 24
MSFT Martin Ratio Rank: 20

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRSP vs. MSFT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and Microsoft Corporation (MSFT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CRSP	MSFT	Difference
Sharpe ratio: Return per unit of total volatility	0.33	-0.70	+1.03
Sortino ratio: Return per unit of downside risk	0.94	-0.84	+1.79
Omega ratio: Gain probability vs. loss probability	1.11	0.89	+0.22
Calmar ratio: Return relative to maximum drawdown	0.49	-0.53	+1.02
Martin ratio: Return relative to average drawdown	0.81	-1.08	+1.89

CRSP vs. MSFT - Sharpe Ratio Comparison

The current CRSP Sharpe Ratio is 0.33, which is higher than the MSFT Sharpe Ratio of -0.70. The chart below compares the historical Sharpe Ratios of CRSP and MSFT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

CRSP vs. MSFT - Drawdown Comparison

The maximum CRSP drawdown since its inception was -85.11%, which is greater than MSFT's maximum drawdown of -69.38%. Use the drawdown chart below to compare losses from any high point for CRSP and MSFT.

Drawdown Indicators

	CRSP	MSFT	Difference
Max Drawdown Largest peak-to-trough decline	-85.11%	-69.38%	-15.73%
Max Drawdown (1Y) Largest decline over 1 year	-42.25%	-33.91%	-8.34%
Max Drawdown (3Y) Largest decline over 3 years	-64.91%	-33.91%	-31.00%
Max Drawdown (5Y) Largest decline over 5 years	-80.68%	-37.15%	-43.53%
Max Drawdown (10Y) Largest decline over 10 years	—	-37.15%	—
Current Drawdown Current decline from peak	-76.29%	-27.46%	-48.83%
Average Drawdown Average peak-to-trough decline	-49.24%	-21.78%	-27.46%
Ulcer Index Depth and duration of drawdowns from previous peaks	25.51%	16.48%	+9.03%

Volatility

CRSP vs. MSFT - Volatility Comparison

CRISPR Therapeutics AG (CRSP) has a higher volatility of 18.22% compared to Microsoft Corporation (MSFT) at 10.52%. This indicates that CRSP's price experiences larger fluctuations and is considered to be riskier than MSFT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRSP	MSFT	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.22%	10.52%	+7.70%
Volatility (6M) Calculated over the trailing 6-month period	43.62%	22.31%	+21.31%
Volatility (1Y) Calculated over the trailing 1-year period	62.44%	25.42%	+37.02%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	60.65%	26.66%	+33.99%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	64.35%	27.06%	+37.29%

Dividends

CRSP vs. MSFT - Dividend Comparison

CRSP has not paid dividends to shareholders, while MSFT's dividend yield for the trailing twelve months is around 0.91%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CRSP CRISPR Therapeutics AG	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
MSFT Microsoft Corporation	0.91%	0.70%	0.73%	0.74%	1.06%	0.68%	0.94%	1.20%	1.69%	1.86%	2.37%	2.33%

Financials

Frequently Asked Questions

Can I hold both CRSP and MSFT in my portfolio?

CRSP and MSFT have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CRSP or MSFT?

CRSP has higher volatility (18.22%) compared to MSFT (10.52%). In terms of maximum drawdown, CRSP dropped -85.11% vs MSFT's -69.38%.

Which has better risk-adjusted returns?

CRSP currently has the higher Sharpe Ratio (0.33 vs -0.70), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.